The therapeutic anti-diabetic effect of SMK001, a poly herbal formula was evaluated in the streptozotocin (STZ; 60 mg/kg, single intraperitoneal injection) induced diabetic rats. For therapeutic study, test articles were orally dosed once a day from 21 d after STZ-dosing at 100, 200 and 500 mg/kg/5 ml dosage levels for 4 weeks. The body weight changes, blood and urine glucose level changes were monitored with changes on the pancreas weight, and after sacrifice, the histopathological changes of pancreas and the changes of insulin-and glucagonproducing cells were also observed by immunohistochemistry. The results were compared to that of glibenclamide 5 mg/kg-dosing group. Significantly ( pϽ0.01 or pϽ0.05) decrease of body weight, blood and urine glucose levels were detected in STZ-induced diabetic animals with disruption and disappearance of pancreatic islets. In addition, significantly (pϽ0.01) increase of glucagon-and decrease of insulin-producing cells were detected in STZ induced diabetic rats. However, these diabetic changes were significantly ( pϽ0.01 or pϽ0.05) and dose dependently decreased in SMK001-dosing groups, and SMK001 100 mg/kg showed more favorable effects compared to that of glibenclamide 5 mg/kg. Based on these results, it is considered that SMK001 has favorable effect to inhibit the changes on the blood and urine glucose levels, body weight and the histopathological changes of pancreas in STZ induce diabetes.
Diabetes is likely to remain a significant threat to public health in the years to come. In the absence of effective and affordable interventions for both types of diabetes, the frequency of the disease will escalate worldwide, with a major impact on the population of developing countries. 2) In modern medicine, the beneficial effects on glycemic levels are well documented; the preventing activity of these drugs against progressive nature of diabetes and its complications was modest and not always effective. Insulin therapy affords effective glycemic control, yet its short comings such as ineffectiveness on oral administration, short self life, requirement of constant refrigeration, and in the event of excess dosage-fetal hypoglycemia limits its usage.
3) Treatment with sulfonylureas and biguanides is also associated with side effects. 4) For various reasons in recent years, the popularity of complementary medicine has increased. Survey conducted in Australia and U.S. indicate that almost 48.5% and 34% respondents had used at least one form of unconventional therapy including herbal medicine. 5) WHO (1980) has also recommended the evaluation of the plants effective and in conditions where we lack safe modern drugs. 6) This leads to increasing demand for herbal products with anti-diabetic activity and less side effects. In addition, the selection of herbal products to efficacy test is relatively easy because they have been used as folk medicine as long times. 7) Streptozotocin (STZ) is the drugs that selectively destroy B cells, insulin-producing pancreatic endocrine cells, and thus induce experimental diabetes mellitus. A major disadvantage with these chemical techniques is that all of these agents induced side effects, which include liver and kidney injuries and bone marrow depression. STZ is less toxic than alloxan and may be useful clinically to treat tumors of B cells, called insulinomas (Hsu and Crump, 1989; Brenna et al., 2003) . 8, 9) The STZ-induced diabetic rat models have been regarded as one of generally used animal model to detect the efficacy of test articles on the diabetes, and the efficacy of test materials are based on the changes of blood and urine glucose levels, body weight and of histopathology of pancreas. 7) Generally, destroy of B cells are initiated from 3 d after STZ-dosing and reach the peak at 3-4 weeks. 10, 11) Thus, the dosing of test articles should be initiated at least 21 d after STZ-dosing in case of therapeutic study.
Glibenclamide is an oral sulphonylurea anti-diabetic preparation with a hypoglycemic effect. Glibenclamide is indicated as an adjunct to diet to lower the blood glucose level in patients with non-insulin dependent (Type 2) diabetes mellitus whose hyperglycemia cannot be controlled by diet alone. 12, 13) Although glibenclamide has been showed various side effects, [13] [14] [15] it was generally used as reference drugs in anti-diabetic activity test. 16, 17) SMK001, a poly herbal formula is consist of several types of water extracts including Coptidis Rhizome (Coptis chinensis) and Trichosanthis Radix (Trichosanthes kirilowii), and known as Dang-Nyo-So-Ko in Korea. SMK001 has been used for treatment of diabetes in Korea as Chinese medicine. However, the anti-diabetic effect of SMK001 has not been evaluated yet in diabetic animals.
In the present study, the therapeutic anti-diabetic effect of SMK001, a poly herbal formula was evaluated in the STZ induced diabetic rats. For therapeutic study, test articles were orally dosed once a day from 21 d after STZ-dosing at 100, 200 and 500 mg/kg/5 ml dosage levels for 4 weeks, and the effects were compared to that of glibenclamide 5 mg/kg-dos- ing level.
MATERIALS AND METHODS

Experimental Animals
Sixty female Sprague-Dawley rats (6-week old upon receipt, Charles River, Japan) were used after acclimatization for 7 d. Animals were allocated 5 per polycarbonate cage in a temperature (20-25°C) and humidity (30-35%) controlled room. Light : dark cycle was 12 h : 12 h and feed (Samyang, Korea) and water were supplied free to access. About half of healthy animals were selected at 21 d after STZ-dosing or Sham injection base on the blood glucose levels. The experimental protocols were conducted in accordance with internationally accepted principles for laboratory animal use and care as found in the Korea Food and Drug Administration guidelines.
Test Articles, Grouping and Dosing SMK001 and glibenclamide (Sigma, U.S.A.) are used in this study. SMK001 was purchased commercially (Lot No. 2004-06, Kang Seock Man Oriental Medical Clinic, Korea) and it is extract by boiling after mix of several herbs. SMK001 stored in a refrigerator at 4°C to protect from light and degeneration. SMK001 was suspended in distilled water and administered at dosage 100, 200 or 500 mg/kg/5 ml base on the body weight at dosing from 21 d after STZ-dosing once a day for 4 weeks. The highest dosage of SMK001 used in this study was selected as the 10 folds higher than that of human use based on the body weight. In addition, glibenclamide was dosed at 5 mg/kg/5 ml as previously.
18) The administered dosage and schedule of these drugs were shown in Table 1 .
Induction of Experimental Diabetes Diabetes is induced by 60 mg/kg/5 ml of STZ was once dosed by intraperitoneal injection dissolved in 50 mM Citrate buffer, and equal volume of buffer was dosed in Sham using same route as previously. 19) Body Weight Changes Body weight was measured at STZ-dosing, and after 21 d of STZ-dosing, the body weight of experimental animals was measured once a week with at sacrifice. Before blood collection, at dosing and sacrifice day, experimental animals were overnight fasted (water was not restricted) to reduce the erratum of feeding.
Blood and Urine Glucose Level Detection For detecting the blood glucose levels, blood were collected at 1 d before STZ dosing, 21 d after STZ-dosing, and at sacrifice (28 d after dosing) from orbital plexus, and collected bloods were deposited into NaF glucose vacuum tube (Becton Dickinson, U.S.A.) for plasma separation. At same time, 2 ml of urine were collected and at 3000 rpm for 15 min under room temperature using NaF glucose vacuum tubes. Blood and urine glucose levels were detected using automated analyzer (Toshiba 200 FR, Japan).
Pancreas Weight Changes At sacrifice, the weight of pancreas (including duodenal and splenic lobes) was calculated at g levels and to reduce the erratum rose from individual body weight differences, the relative weight (%) was calculated using body weight at sacrifice and absolute weight as following equation relative pancreas weight (%) ϭ[(absolute pancreas weight/body weight at sacrifice)ϫ100]
Histological Procedures Samples from the splenic lobes of pancreas were fixed in Bouin's solution. After paraffin embedding, 3-4 mm serial sections were prepared and stained with Hematoxylin and eosin for light microscopic examination of the normal pancreatic architecture.
Immunohistochemistry Other sections were used for immunostaining using the peroxidase anti-peroxidase (PAP) method. 20) Blocking of nonspecific peroxidase reactions was performed with methanol containing 0.1% H 2 O 2 and to avoid non-specific reactions with the background, the sections were incubated with normal goat serum prior to incubation with the specific antibodies against insulin (dilution, 1 : 2000, Diasorin, U.S.A.) and glucagon (dilution, 1 : 2000, Diasorin, U.S.A.). After rinsing in phosphate buffered saline (PBS; 0.01 M, pH 7.4), sections were incubated with secondary antibodies (goat anti-rabbit IgG or goat anti-guinea pig IgG, dilution, 1 : 200; Sigma, U.S.A.). Sections were then washed in PBS buffer and finally incubated with PAP complex (dilution, 1 : 200; Sigma, U.S.A.). The peroxidase reaction was carried out using a solution 3,3Ј-diaminobenzidine tetrahydrochloride containing 0.01% H 2 O 2 in Tris-HCl buffer (0.05 M, pH 7.6). After staining, sections were analyzed with the use of a light microscope. After immunostained, the sections were lightly counterstained with Mayer's Hematoxylin and the IR cells were observed under light microscope. The specificity of each immunohistochemical reaction was determined as recommended by Sternberger, 20) including the replacement of specific antiserum by the same antiserum, which had been preincubated with its corresponding antigen-insulin and glucagon.
Histomorphometry Numbers of islets, insulin-and glucagon-producing cells are calculated in total 10 parts of pancreatic parenchyma as previously. 21) The pancreatic islet numbers are detected as N/mm 2 of pancreatic parenchyma, and insulin-and glucagon-producing cells as N/200 mm 2 of islet regions using automated image analysis process (Soft Image System, Germany) attached to light microscopy.
Statistical Analyses Results are expressed as the meanϮ S.D. Mann-Whitney U-Wilcoxon Rank Sum W test (MW test) was used to analyze the significance of data with SPSS for Windows (Release 6.1.3, SPSS Inc., U.S.A.) and a pvalue of less than 0.05 was considered to be a significant difference. (pϽ0.05) and dose dependently increased compared to that of Control from 14 d after dosing. In glibenclamide 5 mg/kgdosing group, no significant changes compared to that of Control were detected ( Table 2) .
RESULTS
Changes of Body Weights
Changes of Blood Glucose Levels In the diabetic Control, significantly (pϽ0.01) increase of blood glucose levels was detected compared to that of Sham but these abnormal increases on blood glucose levels were significantly (pϽ0.01 or pϽ0.05) and dose-dependently decreased in SMK001-dosing groups compared to that of Control at 28 d after dosing. In glibenclamide 5 mg/kg-dosing group, a significant (pϽ0.05) decrease of blood glucose levels compared to that of Control was also detected at sacrifice (Table 3) .
Changes of Urine Glucose Levels In the diabetic Control groups, significantly ( pϽ0.01) increase of urine glucose levels were detected compared to that of Sham but these abnormal increases on urine glucose levels were significantly (pϽ0.01 or pϽ0.05) and dose-dependently in SMK001-dosing groups as blood glucose levels compared to that of Control. In glibenclamide 5 mg/kg-dosing group, a significant (pϽ0.05) decrease of urine glucose levels compared to that of Control was also detected at sacrifice (Table 4) .
Pancreas Organ Weight Changes Although significantly (pϽ0.01 or pϽ0.05) increase of absolute weight of pancreas was detected in all SMK001-dosing groups, no SMK001-and glibenclamide treatment-related changes on the relative pancreas weight were detected in the present study (Table 5) .
Histopathological Changes of Pancreas In the diabetic Control, decrease of pancreatic islet numbers and their size, atrophy and vacuolation and invasion of connective tissues in parenchyma of pancreatic islets were detected but these abnormal histological signs were dramatically and dose-dependently decreased in SMK001-dosing groups compared to that of Control. Dramatical but slighter effects than SMK001 on the histopathological changes of the pancreas were observed in glibenclamide 5 mg/kg-dosing group (Fig. 1) . At histomorphometrical analysis, a significantly (pϽ0.01) decrease of pancreatic islet numbers were detected in Control compared to that of Sham. However, the number of pancreatic islets were significantly (pϽ0.01 or pϽ0.05) increased in all SMK001-dosing groups compared to that of Control with dose-dependency. In glibenclamide-dosing group, quite similar islet numbers were detected compared to that of Control (Table 6) .
Changes of Insulin-Producing Cells In the diabetic Control, the numbers of immunoreactive insulin-producing cells were reduced and they were distributed in restricted pancreatic islets but these abnormal changes on the insulinproducing cells were dramatically and dose-dependently inhibited by SMK001-dosing (Fig. 2) . At histomorphometrical analysis, a significantly (pϽ0.01) decrease of insulin-producing cells were detected in Control compared to that of Sham. However, the number of insulin-producing cells were significantly (pϽ0.01) and dose-dependently increased in all SMK001 and glibenclamide-dosing groups compared to that of Control, and the more dramatically changes were detected in SMK001-dosing groups compared to that of glibenclamide 5 mg/kg-dosing group (Table 6) .
Changes of Glucagon-Producing Cells In the diabetic Control, the numbers of immunoreactive glucagon-producing cells were increased and they were distributed throughout the whole pancreatic islets but these abnormal changes on the glucagon-producing cells were dramatically and dose-dependently inhibited by SMK001-dosing (Fig. 3) . At histomorphometrical analysis, a significantly (pϽ0.01) increase of glucagon-producing cells were detected in Control compared to that of Sham. However, the number of glucagonproducing cells were significantly ( pϽ0.01) and dose-dependently decreased in all SMK001 and glibenclamide-dosing groups compared to that of Control, and the more dramatically changes were detected in SMK001-dosing groups compared to that of glibenclamide 5 mg/kg-dosing group (Table 6 ).
DISCUSSION
STZ is the drugs that selectively destroy B cells, insulinproducing pancreatic endocrine cells, and thus induce experimental diabetes mellitus. 8, 9) In our study we have found that the continuous treatment with SMK001 for a period of 28 d produced a significant decrease in the blood and urine glucose levels of STZ-diabetic rats with inhibit the decrease of Note that well arranged cords of insulin-producing cells were detected throughout the whole pancreatic islets of Sham. However, only a few cells were distributed in the central regions of pancreatic islets of Control. These abnormal changes on the insulinproducing cells were dramatically reduced in all test article dosing groups compared to that of Control. PAP methods; scale barsϭ200 mm. insulin-producing cells in the pancreatic islets and consequently inhibit the increase of glucagon-producing cells. The treatment of SMK001 in the present study initiated from 21 d after STZ-dosing for observing the therapeutic anti-diabetic effects. Although the exact or involved mechanism of SMK001 on the diabetes process is unclear, the possible mechanism by which SMK001 brings about its hypoglycemic action may be potentiating the insulin effect of plasma by increasing either the pancreatic secretion of insulin from the B cells of pancreatic islets or directive protection of B cells. In this context a number of other herbal extracts or poly herbal formula have also been observed to have hypoglycemic effects. 3, 22) Hyperglycemia and increase of urine glucose excretion is the most critical problems in the diabetes. Therefore, the hypoglycemic effect and consequently decrease of urine glucose excretion have been treated as one of the essential characteristics of anti-diabetic agents, 23) and the efficacy of herbal extracts has been screened based on hypoglycemic effects. 16, 24) The dose-dependent hypoglycemic effect of SMK001, and decrease the urine glucose levels detected in the present study considered as the direct evidence that SMK001 has relatively favorable anti-diabetic effects. More favorable effects were detected in SMK001 100 mg/kg on the hypoglycemic and decrease of the urine glucose levels compared to that of glibenclamide 5 mg/kg in this study.
Generally, body weight is decreased as progress of diabetes [25] [26] [27] but SMK001 significantly and dose-dependently inhibited the decrease of body weight from 14 d of dosing periods. Inhibits the body weight decrease is also considered as the indication of anti-diabetic activity of SMK001. Although, absolute pancreas weights are decreased in diabetic rats compared to non-diabetic Sham, no meaningful changes were detected in the relative weights. Therefore the decrease of absolute weight detected was considered as the results from decrease of body weights not diabetic changes.
Although this method is generally used, a microscopic observation provided good information about organ morphology and function. In the STZ induced diabetic rats, inflammatory changes were detected in the pancreatic islets results from selectively destroy of insulin-producing B cells and consequently, atrophy and decrease of the numbers of pancreatic islets observed are induced. 10, 28) As diabetic process, atrophy and vacuolation of islet cells according to destroy of B cells were demonstrated in the present study with decrease of the number of observing pancreatic islets on the histomorphometry. However, these changes are dramatically and dose-dependently inhibited by SMK001 treatment, and antidiabetic activities of numerous herbal extracts have been observed base on these histopathology and histomorphometry of the pancreas. 27, 29) Insulin-producing cells are generally located in the central regions and glucagon-producing cells are in the peripheral regions of pancreatic islets, and absolutely more numerous insulin-producing cells are detected compared to that of glucagon-producing cells in vertebra. 21, 30) However, the insulin-producing cells are destroyed and decreased in number, and consequently the relative numbers of glucagon-producing cells are dramatically increased as process of STZ induced diabetes. In addition, rearrangements of glucagon-producing cells are occurred from peripheral regions, they distribute throughout the whole islets. 31, 32) In the present study, the frequency and distribution in the pancreatic islets of insulin-and glucagon-producing cells are changed as previously. 31, 32) However, these changes are dramatically and dosedependently inhibited by SMK001 administration. The antidiabetic activity of extracts of Nigella sativa 33) and some chemicals 34, 35) has been detected base on the immunohistochemical changes of insulin-and glucagon-producing cells.
Despite our current lack of knowledge about the underlying mechanism how the SMK001 can treat diabetes induced by STZ, it is concluded that SMK001 has favorable effect to inhibit the changes on the blood and urine glucose levels, body weight and the histopathological changes of pancreas in STZ induce diabetes. Note that glucagon-producing cells were restricted to the peripheral regions of pancreatic islets of Sham. However, numerous cells were randomly distributed throughout the whole regions of pancreatic islets. These abnormal changes on the glucagon-producing cells were dramatically reduced in all test article dosing groups compared to that of Control. PAP methods; scale barsϭ200 mm.
